November 14th, 2026ObesityWeek 2026: Studies Map GLP-1 Access Gaps, Obesity's CostsResearch at ObesityWeek 2026 tracks rising obesity in Medicare, productivity losses, prior authorization denials, and GLP-1 persistence.Read more
November 12th, 2026Phase 3 Trial Tests Ensifentrine for COPD Exacerbation PreventionMerck has begun the phase 3 ENHANCE-3 trial testing whether ensifentrine added to standard of care prevents COPD exacerbations in high-risk adults.Read more
November 12th, 2026Shifting From Late Rescue to Early COPD Detection and CareExperts at GOLD 2026 say targeted case finding, AI, and guideline-based treatment can close COPD’s diagnostic gap and improve patient outcomes.Read more
November 12th, 2026The Liver Meeting 2026 Highlights Hepatitis Delta, PBC Targets, MASH CostsPhase 3 hepatitis delta data, MASH persistence and cost findings, and new PBC treatment targets led The Liver Meeting 2026 in Denver, Colorado.Read more
November 11th, 2026Shorter Telomeres Tied to UIP Pattern, Not Fibrosis Extent, in ILDShorter telomere length was linked to a usual interstitial pneumonia pattern (UIP) on CT in patients with ILD, per research presented at CHEST 2026.Read more
November 10th, 2026FDA Approves Asundexian, First FXIa Inhibitor to Prevent Repeat StrokeThe FDA approved asundexian (Sunharbo) with antiplatelet therapy to reduce recurrent stroke risk after noncardioembolic stroke or high-risk TIA.Read more
November 9th, 2026Phase 3 Data Back ALP Normalization as Treatment Goal in PBCElafibranor and seladelpar normalized ALP in most patients with primary biliary cholangitis whose ALP was below the usual escalation threshold. Read more
November 9th, 2026FDA Approves First Dual-Targeted Therapy for Advanced HNSCCThe FDA granted accelerated approval to amivantamab and hyaluronidase for previously treated recurrent or metastatic head and neck cancer.Read more